NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] Come join us at PAGE 2016 to learn more about DDMoRe

From: Cheung, Amy <Amy.Cheung_at_astrazeneca.com>
Date: Fri, 3 Jun 2016 16:09:10 +0000

Come join us at PAGE 2016 to learn more about DDMoRe:

The IMI Drug Disease Model Resources (DDMoRe) consortium has been created t=
o improve and support the quality, efficiency and cost-effectiveness of Mod=
el-Informed Drug Discovery & Development (MID3).

At PAGE, in addition to our F2F workshop prior to the meeting, we will laun=
ch an information booth (Number 15) during the meeting.

Please come and work with us on the Simeoni -TGI model and see what more yo=
u can achieve with the model using the DDMoRe platform: Interoperability Fr=
amework, Model Repository and Thoughtflow with a warfarin model.

Join us to find out more about future training opportunities and gain an un=
derstanding of how DDMoRe will turn into a Foundation and you can participa=
te.

You can also connect to our DDMoRe team at PAGE for more information during=
 the meeting.

DDMoRe team: Wendy Aartsen, Marylore Chenel, Emmanuelle Comets, Lutz Harnis=
ch, Nick Holford, Siv Jönsson, Mats Karlsson, Charlotte Kloft, Paolo Magn=
i, Peter Milligan, Stuart Moodie, Zinnia Parra-Guillen, Maria-Luisa Sardu, =
Mike Smith, Justin Wilkins and many more...

For more information, visit us at www.ddmore.eu<https://urldefense.proofpoi=
nt.com/v2/url?u=http-3A__www.ddmore.eu&d=CwMFAw&c=UE1eNsedaKncO0Yl_u8=
bfw&r=aSA9aPcbOBQ1angNhuCmVWkpA64zspCAu_tkBcrPe1k&m=kmb-9lN24FRNDfTwAeI=
phX3DxwgDkSDLZ7lGILotrJ0&s=Db8Lain-eN_0b8i6WZ2mNAY6vOvq6WmXZuRDRTYaKw4&e=
=>

Amy on behalf of DDMoRe Workpage 8: Communication and Documentation

________________________________

AstraZeneca UK Limited is a company incorporated in England and Wales with =
registered number:03674842 and its registered office at 1 Francis Crick Ave=
nue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient =
only and may contain confidential and privileged information. If they have =
come to you in error, you must not copy or show them to anyone; instead, pl=
ease reply to this e-mail, highlighting the error to the sender and then im=
mediately delete the message. For information about how AstraZeneca UK Limi=
ted and its affiliates may process information, personal data and monitor c=
ommunications, please see our privacy notice at www.astrazeneca.com<https:/=
/www.astrazeneca.com>

Received on Fri Jun 03 2016 - 12:09:10 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request@iconplc.com. Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.